Chronic Malignancies Working Party

CLL & Plasma Cell Disorders

Activities of WP and Subcommittees

Chair: Nicolaus Kröger, Secretary: Stefan Schönland

Subcommittee Chronic Lymphocytic Leukemia

Chair: Johannes Schetelig, Vice–Chair: Michel van Gelder

Numbers of alloHCTs for CLL per year reported to the EBMT were decreasing in last 5 years when new drugs for patients with high-risk CLL became available.

CLL Allogeneic transplants 2004-2016



None of the new drugs has the potential to eradicate the disease. In 2017 first patients with 17p-CLL who had been exposed to ibrutinib, idelalisib and venetoclax were referred for alloHCT.

The CLL sc focuses on studies dealing with Pathway Inhibitors administered prior to and after alloHCT

The major goal of these studies is evaluate safety issues of such treatment sequences and to assess their efficacy in terms of long-term disease control.

Ibrutinib prior to alloHCT: P. Dreger et al.

Ibrutinib for bridging to alloHCT for CLL and MCL does not appear to adversely affect engraftment, GVHD risk, and NRM. Patients who had received ibrutinib for less than 8 months had a relatively high risk of relapse. Therefore, ibrutinib might improve the perspective of chemo-immunotherapy-refractory patients scheduled for alloHCT. Manuscript submitted.

Idelalisib prior to alloHCT: J. Schetelig et al.

Chronic Leukemia and MDS Session.

Wednesday, March 19th, Poster Hall, Poster A143

This early analysis of safety signals suggests that Idelalisib-based salvage therapy immediately prior to alloHCT does not negatively affect engraftment, acute GVHD and very early mortality. Longer follow-up and higher patient numbers are needed in order to fully establish the safety of this treatment sequence and to assess long-term disease-control.

Treatment of relapse after alloHCT in the new Era of new targeted drugs : L. Sellner et al.

Active survey

Preliminary single center analyses suggest that the chances for survival have improved for patients whose CLL relapsed after alloHCT in recent years. Within the framework of a retrospective registry study we will test the hypothesis that access to new drugs impacts on the prognosis of relapsed CLL after alloHCT. To study this question we will analyze data from patients whose CLL relapsed before versus after the new drugs became available. The data which we will collect for this study will also allow to compare the impact of **D**onor **L**ymphocyte **I**nfusions versus chemo-immunotherapy versus new drugs.

CWMP Business meeting

Subcommittees — **EBMT 2018 Lisbon**

MDS & MPN — Monday, March 19th 2018, 07.00-09.00 Room 3A

CLL & PCD — Tuesday, March 20th 2018, 07.00-09.00 Room 3A

CMWP Working Party Session

Monday, March 19th 2018, 09:00 – 10:30 Room 3A

09:00-09:10 Introduction: Nicolaus Kröger, Germany

09:10-09:30 Molecular genetics and transplant outcomes in MDS: Marie Robin, France

09:30-09:50 Transplant indication for plasma cell disorders other than multiple myeloma: Stefan Schönland, Germany

09:50-10:10 Transplant indication for CML in 2018: Yves Chalandon, Switzerland

10:10-10:30 Long term outcome of patients with MDS surviving allogeneic stem cell transplantation: Johannes Schetelig, Germany

Subcommittee Plasma Cell Disorders

Chair: Laurent Garderet, Vice–Chair: Stefan Schönland

Oral Session 4 – Multiple Myeloma
Monday March 19th, Room 5B

15:00 – 15:10 **Impact of cytogenetics on outcome after stem-cell transplantation in multiple myeloma with extramedullary disease** *Nico Gagelmann*

15:10 – 15:20 **The outcome of haploidentical transplantation in patients with relapsed multiple myeloma. An EBMT/CIBMTR report.** *Firoozeh Sahebi*

15:20 – 15:30 **Improved survival after allogeneic stem cell transplantation for light chain amyloidosis** *Stefan Schönland*

Posters
Tuesday March 20th, Poster Area

Poster B224 **Impact of induction regimen duration before autologous stem cell transplantation in myeloma** *Laurent Garderet et al.*

Poster B236 **Treosulphan in salvage allogeneic post single ASCT in MM** *Charlotte Gran et al.*

Poster B377 **Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Myeloma Patients Receiving Plerixafor** *Curly Morris et al.*

Other ongoing studies

Results of allogeneic stem cell transplantation as first line rescue therapy in myeloma patients relapsing to a prior autograft: Role of the conditioning regimen MAC, NMT, RIC, auto-allo *Patrick J. Hayden*

Autologous transplantation in AL amyloidosis Stefan Schönland

Plasma cell leukemia: comparison of auto-allo transplantation vs double auto vs auto *Sarah Lawless*

Outcome of second autologous transplantation in poor mobilizer at the first collection *Matjaz Sever*

Autologous hematopoietic stem cell transplantation for relapsed multiple myeloma performed with cells procured after previous hematopoietic stem cell transplantation *Joanna Drodz*

Light chain deposition disease and ASCT *Nicolaus Kröger*

Dialysis-dependent MM and ASCT: outcome *Anna Waszczuck-Gajda*

Recently Published

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. Sahebi F, Iacobelli S, Sbianchi G, et al. *Biol Blood Marrow Transplant 2018 Jan 12. pii: S1083-8791(18)30021-1.*

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting. Garderet L, Cook G, Auner HW, et al. *Leuk Lymphoma 2017 Apr;58(4):797-808. doi: 10.1080/10428194.2016.1228926. Epub 2016 Sep 21.*

Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. Auner HW, Iacobelli S, Sbianchi G, et al. *Haematologica 2017 Dec 7. pii: haematol.2017.181339. doi: 10.3324/haematol.2017.181339. [Epub ahead of print]*

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT. Gagelmann N, Eikema DJ, Iacobelli S, et al. *Haematologica 2018 Feb 1. pii: haematol.2017.178434. doi:10.3324/haematol.2017.178434. [Epub ahead of print]*

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma. Garderet L, Iacobelli S, Koster L, et al. *Biol Blood Marrow Transplant 2018 Feb 2. pii: S1083-8791(18)30052-1. doi: 10.1016/j.bbmt.2018.01.035. [Epub ahead of print]*